Copper Peptide AHK-Cu vs PTD-DBM
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Tripeptide-3, Ala-His-Lys Copper
AHK-Cu is a synthetic copper-bound tripeptide, alanine-histidine-lysine complexed with a copper ion, engineered mainly for hair and scalp products. It is the lesser-known sibling of the naturally occurring GHK-Cu copper peptide, designed in the lab specifically to push hair follicles to keep growing. It is a cosmetic and research ingredient, not an approved hair-loss drug, and its evidence is essentially limited to one notable lab study.
Also: CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif
PTD-DBM is a synthetic peptide studied for hair regrowth. It pairs a cell-penetrating protein transduction domain with a Dishevelled-binding motif, letting it slip into cells and block CXXC5, a natural brake on the Wnt/beta-catenin pathway that hair follicles use to enter their growth phase. In mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. The honest catch: the entire efficacy record is preclinical and comes mostly from one lab. There are no completed human trials, no regulatory approval, and no proof it works on people. For research use only.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- PTD-DBM has stronger research evidence (Animal Studies) compared to Copper Peptide AHK-Cu (Limited Research).
Detailed Comparison
| Attribute | Copper Peptide AHK-Cu | PTD-DBM |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Copper peptides like AHK-Cu are thought to act as carriers and signals for copper, a metal involved in tissue repair, blood vessel growth and collagen remodeling. In hair, the proposed action centers on dermal papilla cells, the control hub at the base of each follicle that orchestrates the growth cycle. AHK-Cu is hypothesized to keep those cells alive and dividing longer, partly by shifting the balance of survival proteins (more Bcl-2, less Bax) so follicle cells are less likely to enter programmed cell death, which would extend the active growth phase. These are mechanisms observed in cells and isolated follicles, not proven outcomes in people growing hair. | Hair follicles cycle into their growth (anagen) phase when Wnt/beta-catenin signaling switches on. CXXC5 is a negative feedback regulator of that pathway: it binds the intracellular protein Dishevelled (Dvl) and holds Wnt signaling down. PTD-DBM is a short Dvl-binding motif fused to a protein transduction domain (for cell entry) that competitively disrupts the CXXC5-Dvl interaction. With CXXC5 displaced, Dvl is free to activate Wnt/beta-catenin, which drives follicle stem-cell activation, anagen entry, and wound-induced hair neogenesis (new follicle formation in healing skin). It is typically studied together with valproic acid, a GSK-3beta inhibitor that pushes the same pathway from a different angle, so the two produce a synergistic effect greater than either alone. Be blunt: this mechanism is worked out in mice and cell models. The pathway is well characterized, but none of it has been validated in humans. |
| Common Dosing | Limited community data available See research protocols | No official dose. Sold as 1 mg or 5 mg vials, or a ready-made ~0.001% topical spray Once daily to the scalp in most community routines |
| Administration | Topical (scalp serums, solutions) | Topical (applied to skin) in published research; usually co-applied with valproic acid |
| Typical Duration | 3-6 months for visible results | Applied over several weeks in animal studies |
| Best Time to Take | Morning or as directed | Not established (topical in animal studies) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The science here is real but narrow. The anchor study is Pyo and colleagues, published in Archives of Pharmacal Research in 2007, which tested AHK-Cu on human hair follicles and dermal papilla cells outside the body. At very low concentrations it significantly lengthened isolated human hair follicles and increased dermal papilla cell proliferation, while reducing apoptosis markers, and notably the effect followed a tight dose-response curve where higher concentrations stopped working. That is genuine peer-reviewed evidence for a biological effect. What does not exist is the part people actually want: randomized controlled human trials showing that applying AHK-Cu to a scalp regrows hair or thickens it in living people. So the honest read is that AHK-Cu has a plausible mechanism and one credible ex vivo and in vitro study behind it, but its real-world hair-growth benefit in humans is unproven, and most consumer claims extrapolate well beyond what that single study supports. | The core evidence comes from Lee SH and colleagues in the Choi laboratory at Yonsei University (South Korea), published in the Journal of Investigative Dermatology in 2017. In mice, topical PTD-DBM sped up the onset of anagen after shaving and promoted wound-induced hair neogenesis; a combination of 2 mM PTD-DBM and 500 mM valproic acid outperformed 100 mM minoxidil in that model (mM means millimolar, which describes how concentrated the topical liquid was, not a milligram dose). The compound and its CXXC5-targeting mechanism are cited in more recent review articles on Wnt/beta-catenin hair therapies and short peptides for hair loss (2024-2025). What does not exist, as of 2026, is a single completed, peer-reviewed human efficacy trial. There is no FDA approval and no IND on record. Human dosing, safety, pharmacokinetics, and real-world efficacy are all unknown. The preclinical signal is genuinely interesting, but it is a long way from a proven treatment. |
Frequently Asked Questions: Copper Peptide AHK-Cu vs PTD-DBM
What is the difference between Copper Peptide AHK-Cu and PTD-DBM?
Copper Peptide AHK-Cu is a skin & hair peptide that ahk-cu is a synthetic copper-bound tripeptide, alanine-histidine-lysine complexed with a copper ion, engineered mainly for hair and scalp products. it is the lesser-known sibling of the naturally occurring ghk-cu copper peptide, designed in the lab specifically to push hair follicles to keep growing. it is a cosmetic and research ingredient, not an approved hair-loss drug, and its evidence is essentially limited to one notable lab study. PTD-DBM is a skin & hair peptide that ptd-dbm is a synthetic peptide studied for hair regrowth. it pairs a cell-penetrating protein transduction domain with a dishevelled-binding motif, letting it slip into cells and block cxxc5, a natural brake on the wnt/beta-catenin pathway that hair follicles use to enter their growth phase. in mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. the honest catch: the entire efficacy record is preclinical and comes mostly from one lab. there are no completed human trials, no regulatory approval, and no proof it works on people. for research use only. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Copper Peptide AHK-Cu or PTD-DBM?
Neither is universally "better" - the choice depends on your specific goals. Copper Peptide AHK-Cu is typically used for skin & hair purposes, while PTD-DBM is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Copper Peptide AHK-Cu and PTD-DBM be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Copper Peptide AHK-Cu and PTD-DBM together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.